Asset profile

volixibat · Mirum (MIRM)

Indication: primary sclerosing cholangitis
Also known as: IBAT inhibitor

Company

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritu…

Start live analysis of MIRM Run 8-agent AI analysis

On the calendar

Jan 2027

~ Jan 2027

MIRMMirum

volixibat: Phase 2 trial NCT05050136 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

May 4, 2026

12:00 PM

MIRMMirum

Mirum: VISTAS Phase 2b volixibat meets primary endpoint in PSC

Topline resultsSEC 8-K Open record1 update

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 15, 2026

Primary endpoint metFavourable

Mirum: VISTAS Phase 2b volixibat meets primary endpoint in PSC

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

134 of 326 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

MIRMMirumOwner

SEC 8-K May 4, 2026
Company press release May 3, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT02360852	Phase 2	Terminated	Oct 1, 2016	9	0 of 1 sites in the United States
NCT04663308	Phase 2	Active, not recruiting	Feb 20, 2026	182	34 of 103 sites in the United States
NCT02787304	Phase 2	Terminated	Jul 27, 2018	197	49 of 65 sites in the United States
NCT02630875	Phase 2	Completed	Mar 17, 2017	24	0 of 7 sites in the United States
NCT05050136	Phase 2	Active, not recruiting	Jan 1, 2027	333	44 of 130 sites in the United States
NCT04718961	Phase 2	Terminated	Dec 7, 2022	4	7 of 20 sites in the United States

More from Mirum

Other drugs and candidates from the same company tracked in this sector.

brelovitugchronic hepatitis delta virus (HDV)maralixibatcholestatic pruritus in ultra-rare cholestatic liver diseases including biliary atresia zilurgisertibfibrodysplasia ossificans progressiva (FOP)